
Opinion|Videos|July 29, 2024
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement